KIMS · NSE
Krishna Institute of Medical Sciences Limited
₹809.85
+2.27% (+₹18)
Prev. close
₹791.85
Volume
12,42,321
Delivery %
61.2%
As of
18 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About Krishna Institute of Medical Sciences Limited
Krishna Institute of Medical Sciences Limited provides medical and health care services under the KIMS Hospitals brand in India. The company offers arthroscopy and shoulder, cardiology, cardiothoracic and cardiovascular, organ transplant, medical and surgical gastroenterology, hepatology, orthopaedic, neurology, neurosurgery, nephrology, urology, oncology, pediatric, neonatology, obstetrics and gynaecology, fertility, dental science, emergency and critical care, vascular, rehabilitation and physiotherapy services. It also provides pulmonology, diagnostic and imaging, ophthalmology, ENT, rheumatology and clinical immunology, internal medicine, interventional radiology, diabetology, endocrinology, general surgery, infectious disease, dermatology, thoracic surgery, psychiatry, plastic and reconstructive surgery, transfusion medicine, clinical psychology, anesthesiology, and tele medicine services. In addition, the company operates clinical immunology allergy, bone marrow transplantation, hair transplant, andrology, fertility, alzheimer, arthroscopy, bone and joint, breast, dialysis, female urology, IUI, IVF, joint replacement, kidney health and transplant, ICU, spine, stroke, TAVR/TAVI, hepatobiliary surgery, and trauma centers, as well as pain and wellness clinics. Further, it provides bariatric, thoracic, oral maxillofacial, and endovascular surgery services. Krishna Institute of Medical Sciences Limited was incorporated in 1973 and is based in Secunderabad, India.
Details
Sector
Healthcare
Industry
Medical Care Facilities
CEO
Dr. Abhinay Bollineni
Headquarters
Secunderabad
Website
kimshospitals.comExchange
View on NSE ↗Key stats
Market cap
₹33,029.01 Cr
P/E ratio (TTM)
157.3
EPS (TTM)
₹5.15
Beta (1Y · daily vs NIFTY 50)
0.79
Beta (5Y · monthly vs NIFTY 50)
0.78
Shares float
24.90 Cr
EPS · quarter ended Jun 2026
₹1.04
Upcoming earnings
05 Nov 2026
Financial Performance
01 · Financials
FY21 growth needs FY20 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹1,329.94 Cr | ₹1,650.83 Cr | ₹2,197.68 Cr | ₹2,498.14 Cr | ₹3,003.50 Cr | ₹3,904.60 Cr | |
| EBITDA | ₹381.05 Cr | ₹536.05 Cr | ₹644.71 Cr | ₹653.48 Cr | ₹824.00 Cr | ₹817.00 Cr |
| ₹201.22 Cr | ₹332.69 Cr | ₹336.32 Cr | ₹310.15 Cr | ₹384.50 Cr | ₹241.40 Cr | |
| Diluted EPS | ₹5.24 | ₹8.38 | ₹8.41 | ₹7.75 | ₹9.61 | ₹6.03 |
Total expenses (as filed), Employee benefit expense, Other expenses, Other income have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹1,433.00 Cr | ₹1,904.00 Cr | ₹2,901.00 Cr | ₹3,820.00 Cr | ₹5,689.00 Cr | ₹7,691.00 Cr | |
| ₹316.37 Cr | ₹256.53 Cr | ₹678.17 Cr | ₹1,355.50 Cr | ₹2,561.60 Cr | ₹4,252.90 Cr | |
| Stockholders' equity | ₹864.00 Cr | ₹1,387.00 Cr | ₹1,670.00 Cr | ₹1,828.00 Cr | ₹2,138.00 Cr | ₹2,247.00 Cr |
CWIP, Others, Long-term debt, Current (short-term) debt have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹355.97 Cr | ₹520.12 Cr | ₹432.09 Cr | ₹521.09 Cr | ₹581.80 Cr | ₹510.80 Cr | |
| Investing cash flow | ₹-354.18 Cr | ₹-606.48 Cr | ₹-546.89 Cr | ₹-752.56 Cr | ₹-1,116.20 Cr | ₹-1,451.70 Cr |
| ₹9.82 Cr | ₹59.87 Cr | ₹19.64 Cr | ₹216.76 Cr | ₹543.10 Cr | ₹940.30 Cr | |
| Capital expenditure | ₹-94.00 Cr | ₹-170.00 Cr | ₹-575.00 Cr | ₹-647.00 Cr | ₹-1,009.00 Cr | ₹-1,428.00 Cr |
| End cash position | ₹52.13 Cr | ₹25.63 Cr | ₹61.61 Cr | ₹46.89 Cr | ₹56.00 Cr | ₹55.40 Cr |
Debt issued, Debt repaid, Dividends paid have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Jun 21 | Sep 21–Sep 23(9Q) | Dec 23–Mar 25(6Q) | Jun 25–Mar 26(4Q) | Jun 26–Jun 26(2Q) |
|---|---|---|---|---|---|
| Promoter | 38.85% | 38.84% | 38.82% | 34.11% | 32.50% |
| Public | 61.15% | 61.16% | 61.18% | 65.89% | 67.50% |
| Employee trusts | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,837.3 | 37.0 | 5.36 | 13.7% | 0.06 | +11.9% | +11.4% |
| Divi's Laboratories Limited | ₹2.47 L Cr | ₹9,375 | 83.3 | 14.77 | 15.3% | 0.00 | +12.3% | +53.4% |
| Torrent Pharmaceuticals Limited | ₹1.83 L Cr | ₹4,875 | 76.9 | 21.82 | 25.8% | 1.79 | +21.5% | +37.4% |
| Apollo Hospitals Enterprise Limited | ₹1.26 L Cr | ₹8,944.5 | 60.4 | 13.30 | 20.5% | 0.90 | +15.7% | +13.9% |
| Lenskart Solutions Limited | ₹1.18 L Cr | ₹707.2 | 179.9 | 13.48 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.13 L Cr | ₹1,160 | 25.3 | 4.18 | 18.6% | 0.46 | +18.4% | +10.7% |
| Cipla Limited | ₹1.10 L Cr | ₹1,376.3 | 32.5 | 3.19 | 11.3% | 0.02 | +2.1% | -11.8% |
| Laurus Labs Limited | ₹1.05 L Cr | ₹1,954 | 96.4 | 19.86 | 16.8% | 0.48 | +22.0% | +111.6% |
| Max Healthcare Institute Limited | ₹1.01 L Cr | ₹1,049.3 | 69.8 | 9.39 | 13.4% | 0.32 | +19.0% | -10.6% |
| Dr. Reddy's Laboratories Limited | ₹97,876.16 Cr | ₹1,185 | 29.6 | 2.60 | 11.4% | 0.21 | +3.2% | -10.4% |
| Manipal Health Enterprises Limited | ₹97,364.22 Cr | ₹738.95 | 146.6 | 11.56 | 7.8% | 1.53 | +18.0% | — |
| Krishna Institute of Medical Sciences Limited | ₹32,294.90 Cr | ₹809.85 | 154.1 | 14.37 | 10.7% | 1.89 | +28.9% | +9.4% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
IPO documents
Annual reports
Concall transcripts
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Index membership
23 indices
NSE weights are a free-float market-cap-share estimate, not NSE’s own published (and sometimes capped) index weight. BSE weights are BSE’s own published index weight, not an estimate. Indices without weight data are listed without one, in alphabetical order after the weighted ones.
KIMS Share Price rises 3.29%: price action and valuation
Krishna Institute of Medical Sciences Ltd (KIMS) shares rose 3.29% to Rs 781, up from its previous close of Rs 756.1. The company's market capitalization reached Rs 32,428.7 crore. This price movement occurred without a specified company-specific catalyst.